Haemonetics (HAE) Cost of Revenue (2009 - 2026)

Haemonetics has reported Cost of Revenue for 18 years, with the latest figure at $148.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 7.7% year-over-year to $148.1 million; the trailing twelve-month figure through Mar 2026 stood at $546.4 million (down 10.69% YoY), and the FY2026 full-year result was $546.4 million, down 10.69% from the prior year.
• Cost of Revenue for Q1 2026 stood at $148.1 million, up from $136.6 million in the prior quarter.
• The five-year high for Cost of Revenue was $167.4 million in Q1 2024, with the low at $119.2 million in Q3 2022.
• Average Cost of Revenue over 5 years is $143.3 million, with a median of $145.3 million recorded in 2022.
• Year-over-year, Cost of Revenue climbed 20.95% in 2022 and dropped 19.91% in 2025.
• Tracing HAE's Cost of Revenue over 5 years: stood at $146.6 million in 2022, then increased by 8.04% to $158.4 million in 2023, then decreased by 2.14% to $155.0 million in 2024, then slipped by 11.88% to $136.6 million in 2025, then gained by 8.46% to $148.1 million in 2026.
• The last three Cost of Revenue figures came in at $148.1 million (Q1 2026), $136.6 million (Q4 2025), and $132.6 million (Q3 2025), per Business Quant data.

Peer Comparison